Integra Story

IART -- USA Stock

USD 69.24 1.00 1.42%

Macroaxis Story

Integra LifeSciences Accounts Payable Turnover is comparatively stable at the moment as compared to the past year. Integra LifeSciences reported Accounts Payable Turnover of 18.45 in 2020. Accrued Expenses Turnover is likely to gain to 25.49 in 2021, whereas Average Assets are likely to drop slightly above 3.1 B in 2021. Integra LifeSciences is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 18th of February 2021. While some of us are getting worried about healthcare space, it is reasonable to review Integra LifeSciences Holdings using its current fundamental data. We will evaluate why recent Integra LifeSciences price moves suggest a bounce in March. We currently estimate Integra LifeSciences as fairly valued. The real value is approaching 70.08 per share.

Published six days ago

View all stories for Integra Lifesciences | View All Stories

Does Integra LifeSciences (NASDAQ:IART) have stable technical and fundamental indicators based on the newest gain?

Macroaxis provides unbiased trade recommendations on Integra LifeSciences that should be used to complement current analysts and expert consensus on Integra LifeSciences. Our advice engine determines the entity's potential to grow exclusively from the perspective of an investors' current risk tolerance and investing horizon.

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Integra Lifesciences income statement, its balance sheet, and the statement of cash flows. Potential Integra Lifesciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Integra Lifesciences investors may use each financial statement separately, they are all related. The changes in Integra Lifesciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Integra Lifesciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Integra Lifesciences fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Integra Lifesciences performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Integra Lifesciences shares is the value that is considered the true value of the share. If the intrinsic value Integra is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Integra Lifesciences.

Please read more on our fundamental analysis page.

Are Integra Lifesciences Earnings Expected to grow?

The future earnings power of Integra Lifesciences involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Integra Lifesciences factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Integra Lifesciences stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Integra expected earnings.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.

It is good to see analyst projects for Integra Lifesciences, but it might be worth checking our own buy vs. sell analysis

Integra Lifesciences Gross Profit

Integra Lifesciences Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Integra Lifesciences previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Integra Lifesciences Gross Profit growth over the last 10 years.

Please check Gross Profit in more details.

What is driving Integra Lifesciences Investor Appetite?

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Integra LifeSciences is not uncomon. Institutional investors typically avoid acquiring a high percentage of Integra LifeSciences stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Integra is distributed among investors.

Ownership Allocation

Integra LifeSciences secures a total of 84.27 Million outstanding shares. The majority of Integra LifeSciences outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Integra LifeSciences to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Integra LifeSciences Holdings. Please pay attention to any change in the institutional holdings of Integra LifeSciences as this could imply that something significant has changed or about to change at the company. Also note that almost five million fifty-six thousand two hundred invesors are currently shorting Integra LifeSciences expressing very little confidence in its future performance.

Insiders

15.69%

Institutions

90.42%

	Retail Investors	-6.11
	Insiders	15.69
	Institutions	90.42

	2018	2019	2020	2021 (projected)
Interest Expense	64.68 M	53.96 M	62.05 M	50.77 M
Gross Profit	900.95 M	952.88 M	1.1 B	934.42 M

Interest Expense Gross Profit

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Integra LifeSciences has an asset utilization ratio of 77.76 percent. This implies that the company is making $0.78 for each dollar of assets. An increasing asset utilization means that Integra LifeSciences Holdings is more efficient with each dollar of assets it utilizes for everyday operations.

Assets Non Current

2.3 B

Goodwill

1.8 B

Current Assets	854.61 Million	17.2
Assets Non Current	2.26 Billion	45.55
Goodwill	1.84 Billion	37.01
Tax Assets	11.66 Million	0.23

Integra LifeSciences implied volatility may change after the gain

The risk adjusted performance is down to 0.18 as of today. Integra LifeSciences Holdings has relatively low volatility with skewness of 0.01 and kurtosis of -0.06. However, we advise all investors to independently investigate Integra LifeSciences Holdings to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns.

Our Takeaway on Integra LifeSciences Investment

Whereas many of the other players under the medical devices industry are still a bit expensive, Integra LifeSciences may offer a potential longer-term growth to private investors. To conclude, as of the 17th of February 2021, our research shows that Integra LifeSciences is a rather very steady investment opportunity with a below average probability of distress in the next two years. From a slightly different view, the entity currently appears to be fairly valued. Our current 30 days buy-or-sell advice on the firm is Strong Buy.

About Contributor

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Integra Lifesciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC